1. Introduction {#s0005}
===============

Type II endometrial carcinomas, including uterine papillary serous carcinomas (UPSC) and clear cell carcinomas (CC), are generally associated with aggressive clinical behaviors ([@bb0055]). As with colorectal cancer, tumor location has been proposed as a prognostic factor in EC ([@bb0045]). While some studies have analyzed the importance of lower uterine segment involvement (LUSI), they primarily focused on patients with low grade endometrioid tumors ([@bb0050]). The aim of this study was to evaluate the importance of lower uterine segment involvement in type II EC and to determine whether tumor location is correlated with a distinctive molecular profile.

2. Materials and methods {#s0010}
========================

2.1. Study population {#s0015}
---------------------

The study was conducted at the Jewish General Hospital, a tertiary care hospital in Montreal, Canada and approved by Institutional Review Board, protocol \#03-041.

The study cohort included 83 consecutive patients with type II EC (64 patients with UPSC and 19 patients with clear cell carcinoma) out of 544 fully staged patients with EC between the years 2008--2015 ([Fig. 1](#f0005){ref-type="fig"}A). All cases were originally evaluated by a gynecologic pathologist and re-evaluated independently by 2 gynecologic pathologists for this study. A tumor originating in the uterine isthmus was classified as LUS.Fig. 1Study population: A. Selection criteria. B. Patient characteristics, histology, staging and outcomes by tumor location, size and LVSI.Fig. 1

The surveillance period includes routine follow-up examinations every 4 months during the first two years, followed by every 6 months for up to 5 years, and then yearly thereafter. Overall survival (OS) was defined as time from diagnosis to either last follow-up or death. Progression-free survival (PFS) was defined as the time from surgery to either date of recurrence or death. Recurrences were diagnosed clinically or radiologically.

2.2. Sequencing {#s0020}
---------------

Out of 64 patients in the cohort with UPSC, 50 patients had a tumor sample in our tumor bank. Sections (8--12 mm) from fresh frozen surgical tumor samples were cut and stained with hematoxylin and eosin (H&E). Forty-two samples with a serous carcinoma content of over 90% were selected for subsequent analysis. [Fig. 1](#f0005){ref-type="fig"}A illustrates the study population for the genetic analysis. DNA was extracted from the cancer samples using the DNeasy Blood and Tissue Kit (Qiagen, Toronto, ON, Canada). DNA concentration and purity was assessed using the NanoDrop ND-100 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Next Generation Sequencing was performed using the Illumina MiSeq platform (Illumina Inc., San Diego, CA). The list of targeted regions can be found in the supplementary files (Supplementary Table 1). 168 genes were targeted at 420 different mutational hotspots. The library was prepared using the Nimblegene TruSeqLT preparation kit (Illumina Inc., San Diego, CA). The Genome Reference Consortium Human Build 38 (hg38; RefSeq accession: GCF_000001405.26) was used for the reference alignment.

2.3. Mutation analysis {#s0025}
----------------------

The resulting VCF files were annotated in silico using the Ensembl Variant Effect Predictor ([@bb0075]). Since carcinogenic genetic variants are thought to be sporadic in a healthy population, we selected for rare variants using their reported population allele frequency using the gnomAD database ([@bb0040]). Alleles with a population allele frequency below 1.5% were designated as rare and kept for further downstream analysis. Where needed, the raw BAM files were manually visualized using the Integrated Genome Viewer ([@bb0065]) for possible reading mistakes by the variant caller. Synonymous or intronic mutations were also removed from our study, except if the mutation occurred within three base pairs of a coding exon, in which case the mutation was identified as a splice site mutation. Missense mutations were annotated using the following prediction tools: PolyPhen-2 ([@bb0005]), Sift ([@bb0070]), MCAP([@bb0035]), MutationAssessor ([@bb0060]) and REVEL ([@bb0030]).The same mutations were kept for further analysis if they were predicted as pathogenic by at least three out of the five tools. All data manipulations were done using the R program ([www.cran.r-project.org](http://www.cran.r-project.org){#ir0005}).

2.4. Statistical analysis {#s0030}
-------------------------

Statistical analysis was performed using SPSS 24 (IBM Corp, College Station, TX). Statistical significance was calculated using the chi square or the Fisher\'s exact tests for differences in qualitative variables and the Wilcoxon rank sum test for differences in continuous variables.

Kaplan-Meier survival curves were used to calculate survival estimates (PFS and OS) and the log rank test was used in order to quantify survival differences according to different variables. A multivariate analysis using the Cox proportion hazards model was performed to assess the hazard ratio of the prognostic factors for PFS and OS.

3. Results {#s0035}
==========

Out of the 83 patients with type II EC, 26 had LUSI (31.3%) and these were compared to 57 (68.7%) patients with upper uterine tumors. Patient and pathological characteristics and outcomes are summarized in [Fig. 1](#f0005){ref-type="fig"}B. Patients with LUSI, large tumors, and LVSI were more likely to be diagnosed with advanced FIGO (2009) stage disease (III-IV) (*P* \< .01, *P* = .03, and *P* \< .01, respectively).

Data for time-to-event analyses were updated up to September 27, 2016. The median follow-up time for all patients was 45.5 months (range, 1.7--103.6 months). During the follow-up period, 26 women (31.3%) had recurrent disease and 28 died (33.7%). Of the 3 uterine factors studied, LUSI was identified as the only factor associated with disease recurrence. Patients with LUSI had more distant recurrences (50%, 13 out of 26, versus 17.5%, 10 out of 57, *P* = .004) and local recurrences (19.2%, 5 out of 26 versus 3.5%, 2 out of 57, *P* = .03). LUSI was associated with a greater risk of recurrence in stages I-II only (44.4% vs 7.9%, *P* = .018). Presence of LUSI was inversely associated with survival (38.5% versus 78.9%, *P* = .01). [Fig. 2](#f0010){ref-type="fig"} presents the Kaplan-Meier curves for overall survival (OS) and Progression-Free Survival (PFS) in patients with LUSI, tumor diameter larger than 2 cm, and LVSI. On multivariate analysis, LUSI remained the only significant uterine risk factor ([Table 1](#t0005){ref-type="table"}), in addition to age and stage.Fig. 2Kaplan-Meier OS and PFS analyses by: (A,B) Tumor location (LUS vs. upper uterine segment) OS. (C,D) Tumor size (\>2 cm vs. \<2 cm). (E,F) LVSI+ vs LVSI−.Fig. 2Table 1Multivariate analysis - risk factors for recurrence.Table 1PFS 95% confidence intervalOS 95% confidence intervalRisk factorHazard ratioLowerUpper*P*-valueHazard ratioLowerUpper*P*-valueLUS+2.91.36.20.0072.61.15.90.025LVSI+1.50.63.40.382.10.85.50.14Tumor size\>2 cm0.90.32.60.831.20.34.70.78Age (≥65 vs. \<65)2.31.05.00.052.51.046.000.04Stage (I/II vs III/IV)7.83.318.3\<0.0016.92.617.9\<0.001

When analyzing a subgroup of forty-two UPSC samples, using next generation sequencing, 54 out of 168 sequenced genes harbored mutations in forty samples following mutation filtering, as sequencing failed for two samples ([Fig. 1](#f0005){ref-type="fig"}A). Nine of the sequenced tumors originated in the lower uterine segment. [Fig. 3](#f0015){ref-type="fig"}A shows a landscape overview of the frequency of mutated genes, the number of mutations per sample and the type of mutation in function of tumor location in the uterus. Six samples exhibited a hyper-mutated phenotype (*N* \> 8 mutations) due to their increased mutational frequency compared to all other samples. One out of these six samples originated from the LUS. *TP53* was found to be the most commonly mutated gene in the UPSC cohort ([Fig. 3](#f0015){ref-type="fig"}A, 80%), without a statistically significant difference between lower and upper uterine segment tumors (88.9% vs. 77.4%, respectively, *P* = .449, [Fig. 3](#f0015){ref-type="fig"}B). *PPP2R1A* was found to be mutated in 40% of the patients (41.9% and 33.3% of the lower and upper segment tumors, respectively, *P* = .643). *PTEN*, *PIK3CA*, *CDKN2A* and *ARID1A* were found to be mutated only in upper uterine segment tumors (29%, 12.9%, 19.4% and 12.9%, respectively). [Fig. 3](#f0015){ref-type="fig"}B shows the most recurrently mutated genes in our patient cohort (≥10% of the samples). *AKT2* mutation frequencies were found to be significantly different between LUS positive and negative groups (33.3% vs 6.5%, respectively, *P* = .03). A large frequency of mutations within the PTEN-PI3K-AKT signaling axis were found in the tumors from the upper segment only (45%, *P* = .04, [Fig. 3](#f0015){ref-type="fig"}C). No other pathways were found to be differently mutated between the two groups.Fig. 3Somatic mutations profiles of lower uterine segment UPSC versus upper uterine tumors: A. A landscape overview of the frequency of mutated genes, the number of mutations per sample and the type of mutation in function of tumor location in the uterus. B. Frequency of the most mutated genes (≥10%) in lower and upper UPSC tumors. C. Frequency of mutations within the PTEN-PI3K-AKT signaling axis and the mismatch repair pathway in function of tumor location.Fig. 3

4. Discussion {#s0040}
=============

The association between tumors located in the lower uterine segment and worse prognosis has been previously described for type I cancers ([@bb0050]; [@bb0020]). LUSI was associated with pelvic and para-aortic nodal disease, but not with recurrence in a study of 208 patients with high grade EC that included a small subset of 35 serous and 12 clear cell cancers ([@bb0015]).To understand the difference between our results on type II cancers and this study containing a mix of high grade type I cancers and type II cancers, we evaluated a subgroup of high grade, type I cancers and found that using a multivariate analysis, LUSI in high grade type I tumors did not predict adverse outcome (data not shown) in contrast to type II cancers. This suggests that type I and type II high grade cancers are clinically different. In our cohort, with only type II cancers, LUSI was significantly associated with worse outcome.

The frequency of three of four recurrently mutated genes (*TP53*, *PPP2R1A*, *PIK3CA*) concurred with previously described frequencies ([@bb0010]), confirming the serous histology of our samples (Supplementary Table 3). *PTEN* was mutated at a higher frequency in our cohort (22%) than in other studies. A significant difference in the mutation frequency of *AKT2* was observed between the two groups in this study, but three of the five variants were classified as likely benign in the Reference Sequence database (Supplementary Table 2). *FOXL2* was mutated in 33% of all LUSI tumors, but only in 9% of upper uterine segment tumors. The specific mutations have not previously been reported in the COSMIC or RefSeq databases (Supplementary Table 2). The PTEN-PI3K-AKT signaling axis is a known major pathway of carcinogenesis, especially in high-grade Type I endometrial cancer ([@bb0010]). A pathway-driven analysis of UPSC of the upper uterine segment revealed multiple alterations in the PTEN-PI3K-AKT signaling axis (45%). Only one patient with a mutation in this pathway experienced a progression event, and no tumors situated in the lower uterine segment had a mutation in the same pathway. While the LUSI positive group is small (*n* = 9), our post hoc analysis estimated that we could detect a mutation in this pathway in that group, assuming a mutation rate equal to that of the LUSI negative group, with α = 5% and power = 77%. All nine *PTEN* mutations, including the missense mutations, are loss-of-function mutations. Conversely, all four *PIK3CA* mutations, have been described before and annotated as pathogenic in the ClinVar database (Supplementary Table 2) and three of them were mutually exclusive from *PTEN* mutations. Moreover, they are all putative activating mutations due to their location with the C2 functional domain of the protein ([@bb0025]). *TP53* mutations were found in six of the twelve patients mutated in this pathway and the tumors were confirmed to be histologically serous by two different gynecologic pathologists. Together, our results suggest that a significant subset of histologically serous tumors of the upper uterine segment may be driven by endometrioid-like, PTEN-PI3K-AKT oncogenic defects, despite mutations in *TP53.* This may partially explain the difference in outcome between the groups, since patients PTEN-driven serous tumors have better PFS and OS than patients with TP53-driven tumors (Supplementary Fig. 1A--B). However, both groups still fared better than patients with lower uterine segment tumors.

Our results suggest that tumor location in the lower uterine segment is an independent prognostic factor for local and distant recurrence, and survival in type II EC. This study has several limitations: other genetic events may play a significant role in UPSC carcinogenesis, the number of LUS tumors that were analyzed was limited, and somatic copy number alterations and epigenetic events were not considered in this study. The main strengths of this study lie in the fact that this data was collected in a single tertiary center where all the patients were fully staged, treated, and followed up. Finally, the two study cohorts were well balanced with regards to adjuvant treatment received and other clinical factors such as age, ASA, and BMI. All tumor samples underwent pathology review prior to molecular analysis and only tumors with \>90% UPSC were included. Moreover, our stringent mutation filtering pipeline allowed us to preferentially consider genomic mutations most likely to have a deleterious effect in the regression analyses.

In conclusion, our data suggests that LUSI is a significant adverse survival factor, associated with a unique mutational profile. Other well established risk factors in endometrioid type EC such as LVSI and tumor size may not be as relevant in patients with UPSC/clear cell carcinomas. Alternative prognostic markers based on the molecular biology of these tumors should be further investigated in the future in order to offer individualized treatments driven by molecular pathways.
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Supplementary S1 Genomic coordinates of the hotspot sequencing.Image 1Supplementary S2 Review of the frequencies of recurrently mutated genes in serous EC.Image 2Supplementary S3 List of uncovered mutations in a cohort of 40 UPSC.Image 3Supplementary S4 Survival of patients with serous endometrial cancer separated by mutational status and tumor location. A) Progression-Free survival. B) Overall survival.Image 4
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